Gyre Therapeutics (GYRE) Current Taxes (2022 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Current Taxes of $3.1 million for Q1 2026, up 450.26% year-over-year from $569000.0 in Q1 2025, and up 6.5% quarter-over-quarter from $2.9 million in Q4 2025.
Gyre Therapeutics (GYRE) Current Taxes (2022 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Current Taxes for 5 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Taxes rose 450.26% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (up 450.26% YoY), while the FY2025 annual figure was $2.9 million, up 3.85% from the prior year.
- Current Taxes rose to $3.1 million in Q1 2026 per GYRE's latest filing, from $2.9 million in the prior quarter.
- Across five years, Current Taxes topped out at $6.5 million in Q1 2024 and bottomed at $569000.0 in Q1 2025.
- Historically, Current Taxes has averaged $2.9 million across 5 years, with a median of $2.8 million in 2024.
- Annual changes were most pronounced in 2025 — Current Taxes slumped 91.21% — and 2026, when it surged 450.26%.
- Gyre Therapeutics' Current Taxes stood at $2.1 million in 2022, then soared by 140.55% to $5.1 million in 2023, then plunged by 43.98% to $2.8 million in 2024, then gained by 3.85% to $2.9 million in 2025, then rose by 6.5% to $3.1 million in 2026.
- Business Quant data shows GYRE's Current Taxes at $3.1 million in Q1 2026, $2.9 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 49.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 76.32 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 59,089.99 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 2.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.15 Mn |
| Mar 31, 2026 | 3.13 Mn |
| Dec 31, 2025 | 2.94 Mn |
| Sep 30, 2025 | 2.65 Mn |
| Jun 30, 2025 | 1.08 Mn |
| Mar 31, 2025 | 569,000.00 |
| Dec 31, 2024 | 2.83 Mn |
| Sep 30, 2024 | 2.84 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Mar 31, 2024 | 6.47 Mn |
| Dec 31, 2023 | 5.05 Mn |
| Dec 31, 2022 | 2.10 Mn |